Opinion
Video
Author(s):
An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.
Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML
Revisit the OncLive On Air Episodes From February 2024
Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML
UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC